DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Razadyne (Galantamine Hydrobromide) - Summary



RAZADYNEtm ER/RAZADYNEtm (galantamine hydrobromide) is galantamine hydrobromide, a reversible, competitive acetylcholinesterase inhibitor.

RAZADYNEtm ER/RAZADYNEtm (galantamine hydrobromide) is indicated for the treatment of mild to moderate dementia of the Alzheimer's type.

See all Razadyne indications & dosage >>


Media Articles Related to Razadyne (Galantamine)

UNMC statewide study to test new model for caregivers of those with Alzheimer's disease, dementia
Source: Caregivers / Homecare News From Medical News Today [2015.08.20]
The responsibility of caring for loved ones with Alzheimer's disease or dementia can be overwhelming - physically, mentally and financially.

Looking Beyond Amyloid in Alzheimer's Diseases
Source: MedPage Today Psychiatry [2015.08.17]
(MedPage Today) -- Momentum builds for other targets in sporadic disease

Alzheimer's Disease
Source: MedicineNet Advance Medical Directives Specialty [2015.08.13]
Title: Alzheimer's Disease
Category: Diseases and Conditions
Created: 8/26/2008 12:00:00 AM
Last Editorial Review: 8/13/2015 12:00:00 AM

Positive initial phase 2a study data with ANAVEX 2-73 showing early evidence of improving cognition in patients with Alzheimer's disease
Source: Clinical Trials / Drug Trials News From Medical News Today [2015.07.24]
Anavex Life Sciences Corp. has announced initial positive cognitive data for ANAVEX 2-73, the Company's lead investigational oral treatment for Alzheimer's targeting sigma-1 and muscarinic...

Alzheimer's Disease - Test Your Medical IQ
Source: MedicineNet Advance Medical Directives Specialty [2015.03.23]
Title: Alzheimer's Disease - Test Your Medical IQ
Category: MedicineNet Quiz
Created: 2/2/2012 5:35:00 PM
Last Editorial Review: 3/23/2015 4:01:03 PM

more news >>

Published Studies Related to Razadyne (Galantamine)

Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. [2014]
rivastigmine, and memantine for the treatment of AD... CONCLUSIONS: Cholinesterase inhibitors and memantine are able to stabilize or

The prediction of response to galantamine treatment in patients with mild to moderate Alzheimer's disease. [2014]
The prediction of efficacy in long-term treatment of acetylcholinesterase inhibitors (AChEIs) is a major clinical issue, although no consistently strong predictive factors have emerged thus far... Patients who show improvement of episodic memory function during the first 4 weeks of galantamine administration may be likely to particularly benefit from galantamine treatment.

Long-term response to galantamine in relation to short-term efficacy data: pooled analysis in patients with mild to moderate Alzheimer's disease. [2011.03]
BACKGROUND: This analysis aimed to identify an operational, clinically relevant definition of response achieved in short-term clinical trials to support the identification of patients with Alzheimer's disease (AD) who would benefit most from long-term galantamine therapy... CONCLUSIONS: Patients who demonstrate improvement, stability, or limited cognitive decline 2-5 months after reaching maintenance doses of galantamine are more likely to experience continued benefit from long-term galantamine therapy.

Galantamine improves sustained attention in chronic cocaine users. [2011.02]
Chronic cocaine users are known to have cognitive deficits that are predictive of poor treatment response. Whether these deficits improve with medications targeting specific cognitive functions has not been examined in previous studies.

Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. [2011.02]
CONCLUSION: Galantamine showed no ameliorative effects on cognitive measures in this 6month, double-blind study of patients with schizophrenia treated with an assured and stable antipsychotic medication delivery system. Galantamine may not be an appropriate augmentation agent for cognitive impairments in patients with schizophrenia at the dose used. Copyright (c) 2010 Elsevier B.V. All rights reserved.

more studies >>

Clinical Trials Related to Razadyne (Galantamine)

The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning [Active, not recruiting]
The purpose of the study is to see if galantamine HBr (Razadyne) is safe and can help treat problems with thinking and memory caused by electroconvulsive therapy (ECT).

A Single Dose, Cross-Over Bioequivence Study Comparing Galantamine IR (Immediate Release) Table and Galantmine OS (Oral Solution) in Healthy Volunteers [Completed]
The purpose of this open-label, single dose, two-treatment, two-period, cross-over study is to evaluate the pharmacokinetic profile and tolerability of galantamine oral solution and galantamine tablet.

A Study of the Safety and Effectiveness of Galantamine Hydrobromide (REMINYLŪ) in Patients With Alzheimer's Disease [Completed]
The purpose of this study is to evaluate the safety and effectiveness of galantamine hydrobromide (REMINYLŪ) in patients with Alzheimer's disease who have not received or have not responded to treatment with medication similar to galantamine hydrobromide (REMINYLŪ).

Efficacy and Safety of Galantamine for Improving Dysfunction in People With Bipolar Disorder [Recruiting]
This study will examine whether extended release galantamine, a drug approved by the Food and Drug Administration to reduce cognitive impairments in people with Alzheimer's disease, can perform the same function in stable people with bipolar disorder.

Galantamine Effects on Cognitive Function in Marijuana Users [Recruiting]
To evaluate galantamine's effects on cognitive performance in marijuana users. Galantamine, an acetylcholine esterase inhibitor, is approved for treatment of Alzheimer's disease. Current marijuana users show impaired cognitive functioning, which predicts poor treatment response to behavioral treatments in this population. Whether cognitive impairment in marijuana users will improve with medication treatment has not been evaluated. We hypothesize that galantamine, compared to placebo, will improve cognitive performance in marijuana users. Galantamine, compared to placebo, will improve working memory, verbal learning/memory and response inhibition functions in marijuana users.

more trials >>

Page last updated: 2015-08-20

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015